GLP-1 receptor agonists, also known as GLP-1 analogs or incretin mimetics, are a class of drugs that have multiple effects beyond appetite regulation. Let’s explore their mechanism of action and their impact:
1. Mechanism of Action:
GLP-1 agonists work by activating the GLP-1 receptor.
They have several effects:
- Slowing Gastric Emptying: They delay the emptying of the stomach, which helps regulate blood sugar levels.
- Inhibiting Glucagon Release: They reduce the release of glucagon, a hormone that raises blood sugar.
- Stimulating Insulin Production: GLP-1 agonists enhance insulin secretion, leading to better blood sugar control.
- Reducing Hyperglycemia: By the combined effects above, they help manage hyperglycemia in people with type 2 diabetes.
- Reducing Food Intake: GLP-1 agonists also decrease food intake, making them effective for weight management and treating obesity.
2. Clinical Indications:
Type 2 Diabetes: GLP-1 agonists were initially developed for type 2 diabetes.
- The American Diabetes Association (ADA) recommends them as first-line therapy for type 2 diabetes, especially in patients with atherosclerotic cardiovascular disease or obesity.
- They are also used in combination with metformin and can be combined with SGLT2 inhibitors.
- GLP-1 agonists have a lower risk of causing hypoglycemia compared to older insulin secretagogues.
- Recent meta-analyses show improvements in cardiovascular and renal outcomes with GLP-1 analogs13.
Obesity: Some GLP-1 agonists are approved to treat obesity even in the absence of diabetes.
Other Indications: Research is ongoing for their use in non-alcoholic fatty liver disease, polycystic ovary syndrome, and addiction-related diseases
In summary, while appetite regulation is one aspect, GLP-1 agonists primarily target blood sugar control, insulin production, and overall metabolic effects. Their multifaceted action makes them valuable in managing both diabetes and obesity
